相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Absence of CD4(+) T Lymphocytes, CD8(+) T Lymphocytes, or B Lymphocytes Has Different Effects on the Efficacy of Posaconazole and Benznidazole in Treatment of Experimental Acute Trypanosoma cruzi Infection
Marcela L. Ferraz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease
A. Rassi et al.
HEART (2009)
Rational Modification of a Candidate Cancer Drug for Use Against Chagas Disease
James M. Kraus et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up
C. D. Fernandes et al.
MEMORIAS DO INSTITUTO OSWALDO CRUZ (2009)
Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit
Chiung-Kuang Chen et al.
PLOS NEGLECTED TROPICAL DISEASES (2009)
Heteroallyl-containing 5-nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action
Aleiandra Gerpe et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2008)
Persistence of PCR-positive tissue in benznidazole-treated mice with negative blood parasitological and serological tests in dual infections with Trypanosoma cruzi stocks from different genotypes
H. R. Martins et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease
Juan M. Bustamante et al.
NATURE MEDICINE (2008)
The Neglected Tropical Diseases of Latin America and the Caribbean: A Review of Disease Burden and Distribution and a Roadmap for Control and Elimination
Peter J. Hotez et al.
PLOS NEGLECTED TROPICAL DISEASES (2008)
The challenges of chagas disease -: Grim outlook or glimmer of hope?
Rick L. Tarleton et al.
PLOS MEDICINE (2007)
Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidence-based medicine
Rodolfo Viotti et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2007)
Kinetic characterization of squalene synthase from Trypanosoma cruzi:: Selective inhibition by quinuclidine derivatives
Marco Sealey-Cardona et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
The anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole
Marcela L. Ferraz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Pathogenesis of chronic Chagas heart disease
Jose Antonio Marin-Neto et al.
CIRCULATION (2007)
Prevention, control, and elimination of neglected diseases in the Americas: Pathways to integrated, inter-programmatic, inter-sectoral action for health and development
John C. Holveck et al.
BMC PUBLIC HEALTH (2007)
Squalene synthase inhibitors: Clinical pharmacology and cholesterol-lowering potential
Valentine Charlton-Menys et al.
DRUGS (2007)
Chagas disease in the Amazon region
Hugo Marcelo Aguilar et al.
MEMORIAS DO INSTITUTO OSWALDO CRUZ (2007)
Access to diagnosis and treatment of Chagas disease/infection in endemic and non-endemic countries in the XXI century
Luis Villa et al.
MEMORIAS DO INSTITUTO OSWALDO CRUZ (2007)
An overview of Chagas disease treatment
Jean Jannin et al.
MEMORIAS DO INSTITUTO OSWALDO CRUZ (2007)
Chagas disease in Andean countries
Felipe Guhl
MEMORIAS DO INSTITUTO OSWALDO CRUZ (2007)
Etiological treatment in patients infected by Trypanosoma cruzi:: experiences in Argentina
Sergio Sosa-Estani et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2006)
The future of Chagas disease control
Chris J. Schofield et al.
TRENDS IN PARASITOLOGY (2006)
Cytoskeleton reassembly in cardiomyocytes infected by Trypanosoma cruzi is triggered by treatment with ergosterol biosynthesis inhibitors
Dayse T. Silva et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2006)
Long-term cardiac outcomes of treating chronic chagas disease with benznidazole versus no treatment - A nonrandomized trial
Rodolfo Viotti et al.
ANNALS OF INTERNAL MEDICINE (2006)
Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole
G Benaim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
The protein farnesyltransferase inhibitor tipifarnib as a new lead for the development of drugs against Chagas disease
O Hucke et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa
SO Lorente et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2005)
Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations
S Garcia et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease
M Corrales et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Synthesis and biological evaluation of quinuclidine derivatives incorporating phenothiazine moieties as squalene synthase inhibitors
T Ishihara et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2004)
In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi
JA Urbina et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Parasitic diseases of the heart
LV Kirchhoff et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2004)
Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts
PMD Guedes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents
F Buckner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Chagas disease: a role for autoimmunity?
RL Tarleton
TRENDS IN PARASITOLOGY (2003)
Oxidosqualene cyclase inhibitors as antimicrobial agents
JC Hinshaw et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Mechanism of action of 4-phenoxyphenoxyethyl thiocyanate (WC-9) against Trypanosoma cruzi, the causative agent of Chagas' disease
JA Urbina et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors
T Ishihara et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2003)
In vivo pharmacodynamics of a new triazole, ravulconazole, in a murine candidiasis model
D Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Specific chemotherapy of Chagas disease: controversies and advances
JA Urbina et al.
TRENDS IN PARASITOLOGY (2003)
In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease
JA Urbina et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2003)
Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains
JA Urbina et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2003)
Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana
JA Urbina et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2002)
Design, synthesis, and biological evaluation of aryloxyethyl thiocyanate derivatives against Trypanosoma cruzi
E Elhalem et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
The impact of Chagas disease control in Latin America - A review
JCP Dias et al.
MEMORIAS DO INSTITUTO OSWALDO CRUZ (2002)
Chemotherapy of Chagas disease
JA Urbina
CURRENT PHARMACEUTICAL DESIGN (2002)
A critical review on Chagas disease chemotherapy
JR Coura et al.
MEMORIAS DO INSTITUTO OSWALDO CRUZ (2002)
Penetration of ravuconazole, a new triazole antifungal, into rat tissues
H Mikamo et al.
CHEMOTHERAPY (2002)
Treatment of Trypanosoma cruzi-infected children with nifurtimox:: a 3 year follow-up by PCR
A Solari et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)
Parasite persistence in treated chagasic patients revealed by xenodiagnosis and polymerase chain reaction
C Britto et al.
MEMORIAS DO INSTITUTO OSWALDO CRUZ (2001)
Trypanosome and animal lanosterol synthases use different catalytic motifs
BM Joubert et al.
ORGANIC LETTERS (2001)
Parasite persistence in the aetiology of Chagas disease
RL Tarleton
INTERNATIONAL JOURNAL FOR PARASITOLOGY (2001)
Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors
FS Buckner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Cloning and heterologous expression of the Trypanosoma brucei lanosterol synthase gene
FS Buckner et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2000)
Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago
LMG Bahia-Oliveira et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease
MSS Araújo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2000)
Design and synthesis of aryloxyethyl thiocyanate derivatives as potent inhibitors of Trypanosoma cruzi proliferation
SH Szajnman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi
JA Urbina et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives
L Lauria-Pires et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2000)
分享论文
